Charity Chief Executive Goes the Extra Mile

9th October 2015

There aren't many Chief Executives that would pull on their running vests for the charity they head up, but that's exactly what Chris Farrell is doing this weekend.

Chris, who is the CEO of Cavendish Cancer Care in Sheffield, is aiming to complete the Yorkshire Marathon in less than five hours. Cavendish Cancer Care provides a range of complementary therapies for patients, their carers and their children. Therapies include reiki, shiatsu, counselling, hypnotherapy, acupuncture, healing, aromatherapy, physiotherapy, art therapy, herbalism, homeopathy and play therapy. -The training has been hard enough so I am dreading the big day, Chris explains, -but knowing the difference the money I raise will make to local families living with cancer should get me round. Sunday's marathon also coincides with Chris's first anniversary in charge of the Sheffield charity; previously he worked for Macmillan Cancer Support and The Alzheimer's Society. To sponsor Chris, head to www.justgiving.com/chris-farrell3

You might also be interested in

Landmark skills training report calls for wide-ranging reboot of UK system

Thu 6th May 2021

A major new report is calling for a root and branch reform of the UK’s training system to help businesses access the skills they need to boost productivity.

Sheffield Chamber Comments on Sheffield City Region Quarterly Economic Review Q1 2021 Results

Thu 6th May 2021

On 27th April 2021 businesses from across the region gathered to hear the latest results following the Sheffield City Region (SCR) Quarterly Economic Review for Q1.

BCC welcomes ratification of UK-EU TCA but says work remains to be done

Thu 29th April 2021

Speaking after news that the Trade and Co-operation Agreeement has been ratified, Hannah Essex, Co-Executive Director of the BCC, said:

New Figures Show Workforce Growth Expected but Some Sectors Yet to See Signs of Revival

Thu 29th April 2021

The British Chambers of Commerce today released its Quarterly Recruitment Outlook for Q1 2021.